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Introduction: There are increasing concerns regarding the inappropriate use of medicines
with expenditure continuing to grow driven by increasing sales in oncology and orphan
diseases, enhanced by their emotive nature. As a result, even high income countries are
struggling to fund new premium priced medicines. These concerns have resulted in
initiatives to better manage the entry of new medicines and enhance the rational use of
medicines (RUM). However, there is a need to ascertain the current situation. We sought
to address this by developing the Current Obstacles for Rationalizing Use of Medicines in
Europe (CORUM) mapping tool to qualitatively investigate the current situation and
provide analysis of current views on RUM and interventions among key European
payers and their advisers. The ﬁndings will be used to provide future guidance.
Methodology: Descriptive study exploring and identifying perceived gaps to achieving
optimal RUM. The CORUM tool was based on the WHO 12 key interventions to promote
RUM.
Results: 62 participants took part with most respondents believing their country could
improve RUM capacity. This included educational initiatives on the use of clinical
guidelines (90%) and the inclusion of problem-based pharmacotherapy in
undergraduate curricula and for Continued Professional Development. Key challenges
included a lack of regular updates of guidelines, exacerbated by limited funding and a lack
of follow-up to monitor adherence to agreed guidelines. RUM could also be enhanced by
the development of regional formularies as well as implementing Drug and Therapeutic
Committees where these are currently limited. There also needs to be greater co-in.org March 2020 | Volume 11 | Article 1441
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Frontiers in Pharmacology | www.frontiersordination between RUM and Health Technology Assessment activities, with countries
learning from each other.
Conclusion: There is an urgent need to improve RUM through improved educational and
other activities among European countries, with countries learning from each other. This
will involve addressing current challenges and we will be following this up.Keywords: rational use of medicines, Europe, health authorities, initiatives, health technology assessmentINTRODUCTION
The World Health Organization (WHO) estimates that more
than half of all medicines are prescribed, dispensed or sold
inappropriately, and that half of all patients fail to take them
correctly (World Health Organization, 2012; Ofori-Asenso and
Agyeman, 2016). This results in the waste of healthcare resources
as well as leads to health hazards. The situation is even more
critical in lower- and middle-income countries (LMICs) where
expenditure on medicines can be up to 70% of total healthcare
expenditure, much of which is out-of-pocket (Cameron et al.,
2009; Ofori-Asenso and Agyeman, 2016). Expenditure on
medicines has increased since 2015 beyond US$800 billion
(€720 billion) among countries of The Organisation for
Economic Co-operation (OECD) (European Central Bank,
2015; OECD, 2017). This is driven by increased expenditure
on biological medicines, including those for cancer, as well as
new medicines for patients with hepatitis C (OECD, 2017). Total
retail pharmaceutical expenditure in Europe was more than €210
billion in 2016 (adjusting for purchasing power parities), an
increase of 5% since 2010 (OECD/EU, 2018). The increase was
limited by strategies across Europe to enhance the prescribing of
low-cost generics and biosimilars versus originators and
patented products where care is not compromised (Godman
et al., 2014a; Moon et al., 2014; Moorkens et al., 2017; Vogler and
Schneider, 2017; OECD/EU, 2018; Simoens et al., 2018; Godman
et al., 2019a).
Expenditure on cancer medicines is a concern, with global
expenditure in 2017 at US$133 billion (~€ 117 bn) up from US
$96 billion in 2009, and estimated to reach US$200 billion (~ €
176 bn) by 2022 with an average growth rate of 10 to 13% per
year during the coming years (IQVIA Institute for Human Data
Science, 2018). This increase in expenditure will be driven by
anticipated increases in the prices of new cancer medicines and
increased incidence rates with an estimated 21.4 million new
cancer cases globally per year by 2030 up from 18.1 million in
2018 (Chalkidou et al., 2014; Kelly and Smith, 2014; Howard
et al., 2015; Godman et al., 2017; Bray et al., 2018). In addition,
over 500 companies are actively pursuing new cancer medicines
across multiple indications (IMS Institute for Healthcare
Informatics, 2016; Godman et al., 2018), intensifying
expectations for the rising costs for oncology medicines
(Durkee et al., 2016; Haycox, 2016; Godman et al., 2017;
Dolgin, 2018). There are similar concerns and issues with new
medicines for patients with orphan diseases (Simoens et al., 2013;
Godman et al., 2018; Luzzatto et al., 2018) where we are likely toin.org 2see global spending on orphan medicines reaching US$178
billion (~€ 160 bn) per year by 2020 (Brau and Tzeng, 2018).
This will again be enhanced by the number of medicines for
orphan diseases currently available and in development, and
their envisaged prices (Godman et al., 2016; Godman et al., 2018;
Luzzatto et al., 2018).
Overall, the costs of new medicines are a growing concern
across countries driven by changing demographics, rising patient
expectations, single disease treatment guidelines, and the
continued launch of new premium priced medicines (WHO,
2015; Godman et al., 2014b; Godman et al., 2018). This is set to
continue exacerbated by the number of new medicines in
development as well as the emotive nature of disease areas
such as cancer and orphan diseases (Simoens et al., 2013;
WHO, 2015; Haycox, 2016; Cohen, 2017; Goldstein et al.,
2017; Godman et al., 2018; Luzzatto et al., 2018). We are also
seeing high income countries increasingly struggle to fund new
medicines, and this will continue unless actively addressed
(Malmstrom et al., 2013; Ghinea et al., 2015; Godman et al.,
2018; Kwon et al., 2018). These challenges have led to the
development of new models to better manage the entry of new
medicines as well as initiatives to enhance the rational use of
medicines (RUM). These new models include encouraging the
use of biosimilars and multiple sourced products where pertinent
to conserve resources alongside instigating active disinvestment
processes (Godman et al., 2014a; WHO, 2015; Parkinson et al.,
2015; Guerra-Junior et al., 2017; Moorkens et al., 2017; Godman
et al., 2018) as well as a growing use of managed entry
agreements (MEAs). However, there are concerns with MEAs
including the extent and usefulness of any clinical data collected,
as well as the ability to actively monitor the role and value of new
medicines in routine clinical care to provide future guidance
(Ferrario and Kanavos, 2013; WHO, 2015; Garattini and Curto,
2016; Carlson et al., 2017; Ferrario et al., 2017; Garcia-Doval
et al., 2017; Guerra-Junior et al., 2017; Mercer et al., 2017;
Eriksson et al., 2018; Frisk et al., 2018; Alvarez-Madrazo et al.,
2019; Antonanzas et al., 2019; Mueller et al., 2019).
The WHO deﬁnes RUM as “Patients receive medications
appropriate to their clinical needs, in doses that meet their own
individual requirements, for an adequate period of time, and at
the lowest cost to them and their community” (World Health
Organization, 2002; World Health Organization, 2007).
According to the WHO, a sound rational drug use program in
any country involves interventions on three levels. The ﬁrst is on
the level of healthcare authorities that includes setting strategies
for monitoring the use of medicines, second is on the level ofMarch 2020 | Volume 11 | Article 144
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enhancing the use of agreed clinical guidelines, and the third is
on the level of medicines used by consumers, which includes
raising awareness on key aspects of RUM (World Health
Organization, 2012). Whilst these strategies are operational in
a number of countries, they are rarely subjected to a thorough
assessment of their actual impact in practice such as encouraging
the preferential use of multiple sourced medicines where
pertinent without compromising care or encouraging caution
for new medicines where there are concerns with patient safety
(Godman et al., 2010a; Wettermark et al., 2010; Forslund et al.,
2011; Kaplan et al., 2012; Moon et al., 2014; Godman et al.,
2014b; Troncoso and Diogene, 2014; Frisk et al., 2018; Jacobs
et al., 2019). Especially, there seems to be a gap regarding
stakeholder engagement to assess the implementation of these
strategies, or in gathering information about the key challenges
of implementation and ways of circumventing these challenges,
w i th a focus on var i ab l e con tex t s and d i ff e r en t
healthcare ecosystems.
We sought to address this gap by developing the Current
Obstacles for Rationalizing Use of Medicines in Europe
(CORUM) mapping tool. The objective of the CORUM tool
was to qualitatively investigate the current situation and to
provide an in-depth analysis of current views on RUM
interventions among key payers and their advisers among
European countries in addition to the challenges encountered
when attempting to implement these interventions. The ﬁndings
will be used to develop strategies to enhance RUM in Europe
given increasing budgetary and other concerns.METHODOLOGY
General
This is a descriptive study exploring and identifying perceived gaps
to achieving optimal RUM in Europe. The CORUM tool
(Supplementary Appendix 1) was developed by the authors
based on the WHO 12 key interventions to promote RUM
(Table 1) (World Health Organization, 2012). For each key
intervention, we inquired regarding the extent to which














1Frontiers in Pharmacology | www.frontiersin.org 3promote RUM, checked for current obstacles for this intervention to
be realized based on respondents’ experience in his/her own
country, and asked for respondents’ views concerning possible
ways to circumvent these obstacles to enhance the rational use of
medicine within their own country (Supplementary Appendix 1).
The study also embeds considerations from common elements
including cooperation between national organizations that are
traditionally evident in Health Technology Assessment (HTA)
frameworks widely established within member states of the
European Union (EU) (EUnetHTA, 2018; EUnetHTA Mission,
vision and values, 2019; Vella Bonanno et al., 2019). HTA is the
multidisciplinary process to determine the value of a health
technology. The dimensions of value for a health technology may
be assessed by examining intended and unintended consequences of
health technologies, including the clinical, economical, ethical,
social, organizational, and environmental aspects, as well as wider
implications for the patient, relatives, caregivers, and the population.
The overall value may vary depending on the perspective taken, the
stakeholders involved, and the decision context.
We believe this combination of sources was an appropriate
starting point to develop a cross-sectional survey (see CORUM
Mapping Survey) that could be distributed across key
stakeholders in Europe to gather their perception of the
proposed RUM interventions.
Participants
The target audience of the tool could be categorized into two
main groups. The ﬁrst were the policy makers (users of evidence)
who are typically the decision makers responsible for legislating
and implementing frameworks for adopting and monitoring the
use of medicines within their own region or country. The second
group were “technocrats” (suppliers of evidence), who are often
the producers of assessments of medicines or those giving
recommendations that directly or indirectly inﬂuence decisions
regarding RUM based on evidence-based medicine and/or HTA
(Ward et al., 2009).
Sampling for the participants to be surveyed was conducted
based on a purposive non-random sampling technique, which is
typically used for exploratory work such as this study. The
participants who were approached for this initial survey were
stakeholders across various realms of the healthcare community
spread across different geographical locations within Europe.
The participants were primarily members of Piperska Group, a
non-governmental organization which the authors are
also members.
The Piperska Group is a pan-European network of payers
(health insurers), advisers, and academics that researches and
analyzes key health policies and their impact with the aim of
enhancing the health of populations and individual patients in a
sustainable way (Garattini et al., 2008). Activities include
developing new models to improve the managed entry of new
medicines, developing quality indicators for new medicines,
assessing key issues such as MEAs, discussing minimum
effectiveness levels for new cancer medicines, appraising key
issues surrounding personalized medicine and adaptive
pathways as well as potential ways to enhance the prescribing
of low cost generics and biosimilars to release resources to fundABLE 1 | WHO’s 12 Key interventions to promote rational use of medicine.
. Establishment of a multidisciplinary national body to coordinate policies on
edicine use
. Use of clinical guidelines
. Development and use of national essential medicines lists
. Establishment of drug and therapeutics committees in districts and hospitals
. Inclusion of problem-based pharmacotherapy training in undergraduate
urricula
. Continuing in-service medical education as a licensure requirement
. Supervision, audit, and feedback
. Use of independent information on medicines
. Public education about medicines
0. Avoidance of perverse ﬁnancial incentives
1. Use of appropriate and enforced regulation
2. Sufﬁcient government expenditure to ensure availability of medicines
and staff.March 2020 | Volume 11 | Article 144
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valued medicines within agreed budgets (Godman et al., 2013a;
Malmstrom et al., 2013; Godman et al., 2014b; Godman et al.,
2014c; Moon et al., 2014; Campbell et al., 2015; Godman et al.,
2015a; de Bruijn et al., 2016; Ermisch et al., 2016; Wild et al.,
2016; Ferrario et al., 2017; Moorkens et al., 2017; Vella Bonanno
et al., 2017; Godman et al., 2018; Godman et al., 2019b; Vella
Bonanno et al., 2019). In addition, organizing courses to improve
the managed entry of new medicines and prescribing at the
interface (Godman et al., 2012; Bjorkhem-Bergman et al., 2013;
Matusewicz et al., 2015). The various activities and outputs have
been achieved through cooperation and the exchange of ideas
among a wide base of multi-stakeholder groups in Europe. As a
result, this group helps provide European thought leadership
speciﬁcally for constructing policies around enhancing RUM and
related therapies.
Consequently, the Piperska Group was deemed an
appropriate target audience to drive this exploratory mapping
study. Furthermore, we also incorporated a snowball sampling
technique where existing study participants invited future
participants to take part in this survey. Initially, prospective
participants were approached through e-mail, inviting them to
participate in the survey with the potential of forwarding the
survey to known colleagues.
Tool: CORUM Mapping Survey
Development of the Survey
The CORUMMapping Tool is a survey of 9 structured questions
where each question pertains to one of the WHO key
interventions. Although the WHO proposes 12 key
interventions for optimal RUM, we adapted the questions to
combine one or more interventions to avoid a lengthy
questionnaire. The authors established face-validity of the
survey by allowing experts in the ﬁeld including health
authority personnel to read through the survey and share their
feedback. The survey was subsequently reviewed by a
psychometrician to check for common questionnaire errors.
We adjusted the survey based on the received feedback and
subsequently ran a pilot test on a subset of the prospective
participants to enhance the robustness of the survey. The ﬁnal
survey is available as a supplement.
A brief introduction about the survey, its objectives, and the
instructions were contained in the cover page. Each question in
the survey ﬁrst presented one of the key interventions and
subsequently asked the participants to select a score on a 1–5
scale that best represented how strongly they agreed (score 5) or
disagreed (score 1) that the particular intervention is key for
RUM. A 5-point scale is standard tool for research studies such
as this one (Desser et al., 2010; Shrank et al., 2011; Deutsch et al.,
2015; Garcia et al., 2019). Thereafter, the participants rated their
country’s performance with regards to the presented key
intervention. Following this, the participants selected whether
or not they believed there are current challenges to realizing the
presented intervention in addition to clarifying what these
challenges are. The ﬁnal sub-question asked the participants toFrontiers in Pharmacology | www.frontiersin.org 4propose possible solutions to overcome perceived challenges to
implementing the presented intervention.
We used the online website checkmarket.com to build the
questionnaire layout and subsequently deliver it to the
participants. Checkmarket offers a user-friendly platform to
creating, administering, and analyzing online surveys. The
survey ran for 3 months between March and June 2017
although we allowed one week prior to the “active period”
where we sent the invitation e-mails to participants inviting
them to take part. Weekly reminders were sent to participants
requesting them to complete the survey or clarify any questions if
they had any. All communications with participants were
conducted through e-mail.
Analysis
The responses were analyzed to present a frequency distribution
of the answers. We typically consolidated the high-end and low-
end scores in the 1–5 point scale, e.g. strongly disagree and
disagree, for ease of analysis.
The same approach was followed for questions with binary
answers (i.e. yes or no) and multi-select questions. Finally, the
open-answers, where the participants stated possible ways to
address the perceived challenges of achieving optimal rational
use of medicines, were coded and analyzed according to the so-
called 4 E approach (Education, Economics, Engineering, and
Enforcement) ﬁrst discussed by Wettermark et al. (2009a) and
used extensively since then to analyze the inﬂuence of typically
multiple health policy interventions to improve the quality and/
or efﬁciency of prescribing (Wettermark et al., 2009a; Godman
et al., 2010a; Godman et al., 2010b; Voncina et al., 2011; Woerkom
et al., 2012; Fraeyman et al., 2013; Godman et al., 2013b;Moon et al.,
2014; Leporowski et al., 2018; McCabe et al., 2019).
The 4 E’s consolidate the multiple strategies that can be
applied to rationalizing medicine use. Education refers to a
wide range of educational activities ranging from simple
distribution of printed material to more advanced strategies
such as academic detailing and educational visits by trained
facilitators. Academic detailing, sometimes called educational
outreach visits, typically includes a visit of a trained health
professional such as a physician or pharmacist to a general
practitioner in their own setting on a one-on-one basis to
provide information to help change behavior (Grimshaw et al.,
2004; O’Brien et al., 2007; Jin et al., 2012; Chhina et al., 2013;
Costa et al., 2016). Goals can include active dissemination and
discussion on agreed national or regional treatment guidelines
and improving the management of targeted health conditions
(Chhina et al., 2013; Godman et al., 2014d; Costa et al., 2016).
Typically academic detailing is undertaken in one or more visits
and often combined with other strategies to enhance its
effectiveness including audits and other feedback approaches
(O’Brien et al., 2007; Gustafsson et al., 2011; Costa et al., 2016).
Engineering captures strategies that are more organizational
or managerial interventions such as monitoring of prescribing
against agreed targets such as the quality and outcome
framework in the United Kingdom or percentage targets forMarch 2020 | Volume 11 | Article 144
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et al., 2010; Campbell et al., 2011; Godman et al., 2014a).
Economics strategies typically include ﬁnancial incentives or
disincentives to all key stakeholder groups including
physicians, pharmacists, and patients, i.e. ﬁnancial incentives
for achieving agreed prescribing targets and writing annual
reports on potential ways to improve future prescribing
(Godman et al., 2009; Wettermark et al., 2009b; McGinn et al.,
2010; Martin et al., 2014). Finally, Enforcement strategies are
those that include regulations by law such as mandatory generic
substitution or mandatory prescribing restrictions (Godman
et al., 2009; Wettermark et al., 2009a; Wettermark et al., 2010;
Godman et al., 2014d).
We did not seek ethical approval as this study did not involve
patients. This is in line with previous studies undertaken by the co-
authors in related areas including analysis of policies to enhance the
rationale use of medicines as well as seeking a greater role for
biosimilars and generics involving health authority personnel and
their advisers (Godman et al., 2010a; Godman et al., 2010b;
Godman et al., 2014c; Moon et al., 2014; Godman et al., 2015b;
Ferrario et al., 2017; Moorkens et al., 2017; Godman et al., 2019b) as
well as in line with local legislation and institutional guidelines.
Nevertheless, sufﬁcient information was provided to participants
about the objectives of this study in an invitation email and within
the survey instrument (see Supplementary Appendix 1), with
consent sought to gather responses and analyse the results for
research purposes.RESULTS
Response Rate
The link to the survey was eventually emailed to 235 potential
respondents. Overall, 62 professionals completed the
questionnaire giving a response rate of 26% which is in line
with the average response rates for e-mail surveys
(Fincham, 2008).
Table 2 below shows the breakdown of respondents (n =
62) by professional category and European region. The
majority of the participants were from national health
organization bodies (n = 20) followed by academics (n =
19), while the highest portion of respondents were from
Eastern Europe (n = 37). There was also a high percentage
of Piperska member respondents in the health insurance and
national health organization group (56%), with the least
number among healthcare professionals (17%).Frontiers in Pharmacology | www.frontiersin.org 5Capacity for Rational Use of Medicine
The majority of the respondents agreed that the presented ﬁve
interventions are perceived as key contributors for RUM (see
Figure 1). The percentage of agreement ranged from 65% (drug
therapeutic committees, DTCs) to 84% (clinical guidelines).
Respondents subsequently scored the performance of their
countries in achieving the relevant key RUM interventions on a
scale of 1–5, where 1 refers to “Poor performance” and 5 being
“Strong performance”. The percentage of respondents who
believed that their country performed “above average” or
“strongly” ranged between 23 and 34% across all interventions
(Figure 2). The remaining respondents (66–77%) believed that
their country’s performance with achieving RUM capacity was
currently poor, suboptimal, or fair.
The majority of the respondents highlighted that there are
current challenges to instigating appropriate interventions to
enhance RUM (Figure 3). The percentages ranged from 66%
regarding the inclusion of problem-based pharmacotherapy
training to 90% with regard to the use of clinical guidelines.
The two most selected challenges hindering the use of clinical
guidelines were “lack of updated guidelines or prescribed
guidance” and lack of “governmental funding” to maintaining
these guidelines (Figure 4). “Lack of follow-up of adherence to
formularies” was regarded as the greatest challenge to the
development and use of national/regional formularies.
Furthermore, 45% of the respondents selected “lack of
incentives and/or time” as a limitation to establishing DTCs in
districts, regions, and hospitals. Of the respondents, 39% cited
“lack of time” as a challenge to including problem-based
pharmacotherapy training in undergraduate courses, while 45%
of the respondents believed that the lack of government support
hinders initiatives that support RUM such as education,
feedback, and prescription restrictions.
Figure 5 shows the possible solutions proposed by the
respondents to overcome current challenges to promoting
RUM. “Education” was the solution most proposed by the
respondents (46–53%). Proposed activities included creating
RUM guidelines, implementing electronic aids to support
prescription writing and knowledge sharing through
congresses. Initiatives that are categorized as “Engineering”
approaches were the second most proposed strategies to
address potential challenges, which include stronger
involvement of public health authorities and national payers in
promoting RUM strategies. Finally, strategies pertaining to
“Economics” and “Enforcement” solutions were the least
proposed by participants. Examples of these strategies are
increased governmental funding for the implementation of
guidelines including incentives to physicians (Economics) and
payer contractual agreements with prescribers that guidance
must be adhered to (Enforcement).Linkage Between HTA and RUM
We asked respondents what kind of body is responsible for
coordinating RUM initiatives and/or policies in their countries.
Fifty-six percent (n = 35) of total respondents stated that their
country has a body that coordinates RUM initiatives and/orTABLE 2 | Survey Respondents.
Participant Category CE EE NE SE TOTAL, n (%)
Health Insurer 1 2 1 0 4 (7)
Industry 0 7 0 0 7 (11)
National Health Organization 2 10 5 3 20 (32)
Health Care Professional 2 5 3 2 12 (19)
University/Academic 2 13 3 1 19 (31)
TOTAL, n (%) 7 (11) 37 (60) 12 (19) 6 (10) 62 (100)CE, Central Europe; EE, Eastern Europe; NE, Northern Europe; SE, Southern Europe.March 2020 | Volume 11 | Article 144
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national units (HTA entity) within the ministry of health (MoH)
(23%, Table 3). However, 23% of respondents mentioned that
the HTA entity in their respective country (if this exists) is not
involved in coordinating RUM activities. The other selected
types of RUM-coordinating entities varied between being
independent governmental agencies (13%), regulatory
governmental authority (8%), or a payer agency (6%).
Furthermore, 85% (n = 53) of respondents were aware of
WHO Europe as a pan-European stakeholder which advocates
RUM (Table 4), followed by EuNetHTA (68%, n = 42) and
Piperska Group (65%, n = 40).
Our analysis shows that of the countries in which HTA plays
a role in coordinating RUM initiatives, only 27% of theFrontiers in Pharmacology | www.frontiersin.org 6respondents rated their country’s HTA entity as performing
above average or strong, with 31% as fair and 42% as poor or
suboptimal in helping to achieve effective RUM policy co-
ordination. Seventy-seven percent of the respondents
subsequently believed there are certain challenges to their
country’s HTA entities’ contribution to effective RUM policy
coordination. The top two challenges that were mentioned
(Figure 6) included a “lack of political will” (48%) and “Not
enough knowledge in linking RUM function within an HTA
institution” (44%).
To overcome these challenges, the respondents proposed
solutions that fell under Education (39%) such as the inclusion
of RUM-focused courses for undergraduate students within
pharmacy and medical schools. Solutions pertaining toFIGURE 1 | Proportion of respondents who agree/disagree that the interventions listed promote RUM (n = 62).FIGURE 2 | Countries’ performance in achieving the distinct key interventions to promote RUM, as perceived by the respondents (n = 62).March 2020 | Volume 11 | Article 144
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multidisciplinary independent body, while Economics (16%)
highlighted the need for continuous funding to maintain RUM
policies including potential incentives to physicians. No
solutions were proposed under “Enforcement.”
Governance of RUM Mechanisms
The majority of respondents (79%) agreed or strongly agreed
that consumer education is a key intervention to enhancing
RUM. However, only 16% of the respondents rated their
country’s performance to consumer education as being above
average or strong to promoting RUM, with 37% scoring it as fair
and 47% as poor/suboptimal.
Furthermore, 74% believed there are currently challenges to
providing consumer education in the context of RUM, which
need to be addressed. The greatest challenge mentioned was a
“lack of innovative ways to deliver public education in a useful
manner” (52%), followed by “lack of ﬁnancial resources” (40%),
“limited role of professional societies” (35%), and “lack of
technical knowledge” (31%) (Figure 7).
The majority of the respondents cited educational policies
as a means to address the challenges that hinder effective
consumer education (55%). Possible “educational” solutions
that were mentioned included public campaigns via the local
ministry of health in addition to increasing public
understanding of medicines and their use. Engineering
strategies such as further regulations on medicinal
marketing was cited by 17% of respondents, and ﬁnally 23%
cited ﬁnancial resources as one strategy to support patient
education around RUM.
Role of Pan-European Groups
The top 3 organizations that respondents are aware of in the
realm of RUM were WHO Europe (85%), EuNetHTA (68%),
and the Piperska Group (65%) (Table 4), with a lower number
aware of the European Association for Clinical Pharmacology
and Therapeutics (EACPT—18%).Frontiers in Pharmacology | www.frontiersin.org 7Increasing RUM Impact
Among the respondents, 73% agreed or strongly agreed to the
need for organizations that are enhancing knowledge sharing
and cooperation between stakeholders across Europe with
regards to RUM. However, 56% of respondents believed there
are current challenges that hinder these organizations with
enhancing RUM across Europe. The challenge that was mostly
mentioned by respondents was “Financial support” (37%)
(Figure 8). Finally, the majority of the solutions cited by
respondents to address these challenges were again Educational
policies (43%) such as communication of research results
between these groups, followed by Engineering policies (28%)
inc luding s t ra teg ic a l l i ances among var ious pan-
European groups.DISCUSSION
The results of our study point to the use of clinical guidelines as
the most important key intervention to enhance RUM
(Figure 1). Whilst clinical guidelines have been instrumental
in optimizing care and promoting RUM across settings (Ament
et al., 2015; Colbeck et al., 2016; Ebben et al., 2018; Brouwers
et al., 2019; Niaz et al., 2019; Richards et al., 2019), there are
challenges such as regularly updating the guidance or sufﬁcient
government or health authority funding for their development
and active dissemination in the ﬁrst place. There can also be
concerns with conﬂicts of interest among guideline developers
unless adequately addressed such as the “Wise List” and
guidance in Stockholm, Sweden (Gustafsson et al., 2011;
Bjorkhem-Bergman et al., 2013; Shnier et al., 2016; DeJong and
Steinbrook, 2018; The Lancet, 2019). Addressing the reasons
behind the lack of funding for their dissemination, including how
technology can assist with their wider dissemination and
usability in practice to promote RUM, should be explored
further. This is particularly important in situations whereFIGURE 3 | Proportion of respondents perceiving that there are challenges to realizing the key interventions to promote RUM (n = 62).March 2020 | Volume 11 | Article 144
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companies with the potential for bias (Spurling et al., 2010; Riaz
et al., 2015; Fickweiler et al., 2017; Fadare et al., 2018; Khazzaka,
2019; Ogunleye et al., 2019), although ethical codes of practiceFrontiers in Pharmacology | www.frontiersin.org 8are increasing across countries to address such concerns (Francer
et al., 2014). As a result, there might be a need in some countries
to develop a better understanding of mechanisms to ensure
continuous updating and dissemination of clinical guidance asFIGURE 4 | Current challenges to the implementation of key interventions aimed to promote RUM (n = 62).March 2020 | Volume 11 | Article 144
Gad et al. CORUM in EuropeFIGURE 5 | Possible solutions to address identiﬁed challenges regarding the key interventions to promote RUM (n = 62).TABLE 3 | Types of HTA entities that are involved with RUM policy initiatives and/or coordination as per respondents’ answers (n = 62).
Type of HTA entity Proportion of respondents, % (n)
No HTA entity involved with RUM policy coordination 23% (14)
Government national unit (within MoH) 23% (14)
Government agency (independent) 13% (8)
Regulatory authority national government 8% (5)
Funding agency (i.e. payer) 6% (4)
Professional society (national) 5% (3)
Academia 5% (3)
More than one entity 5% (3)
Network of HTA agencies (more than one country) 3% (2)
Healthcare provider under MoH (e.g. public hospital) 3% (2)
Regional drug agency 2% (1)
Public insurance agency 2% (1)
Professional society—international 2% (1)
Network of HTA agencies (within one country) 2% (1)Frontiers in Pharmacology | www.frontiersin.org Ma9HTA, health technology assessment; RUM, rational use of medicine; MoH, Ministry of Health.TABLE 4 | Proportion of respondents who are aware of the different Pan-European groups advocating RUM (n = 62).
Pan-European Group Proportion of respondents aware, % (n)
WHO Europe 85% (53)
EuNetHTA 68% (42)






Others 13% (8)WHO, World Health Organization; EuNetHTA, European network for health technology assessment; MEDEV, The Medicine Evaluation Committee; HTAi, Health Technology Assessment
International; EuroDURG, European Drug Utilisation Research Group; PPRI, Pharmaceutical pricing and reimbursement information initiative; EACPT, European Association for Clinical
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Gad et al. CORUM in Europewell as continual professional development around clinical
pharmacology and RUM. In addition, ensuring in the future
that clinical guidance is readily accessible in an easy-to-ﬁnd
manner through Apps or other mechanisms during clinic visits
and other patient interactions to improve their utility. There are
concerns with RUM if clinical guidelines are not readilyFrontiers in Pharmacology | www.frontiersin.org 10accessible or utilized (Md Rezal et al., 2015; Mashalla et al.,
2016; Matsitse et al., 2017); alternatively, where physicians are
overloaded with guidelines and where they have doubts about
them (Sermet et al., 2010). We do know that if physicians trust
key personnel involved in the development of prescribing
guidance, there is a comprehensive dissemination strategy andFIGURE 6 | Challenges hindering the countries’ HTA entities to achieving effective RUM policy coordination (n = 62).FIGURE 7 | Challenges hindering achieving the key interventions to promote RUM (n = 62).March 2020 | Volume 11 | Article 144
Gad et al. CORUM in Europeprescribing is regularly monitored, there is high adherence to any
prescribing guidance produced. This is illustrated by high
adherence rates to recommended treatment guidance in
Stockholm County Council in Sweden with their “Wise List” of
medicines and guidelines (Gustafsson et al., 2011; Bjorkhem-
Bergman et al., 2013; Eriksen et al., 2017; Eriksen et al., 2018).
There are concerns though that DTCs recorded the lowest
percentage of being key for promoting RUM (Figure 1). The
relatively high percentage of neutral responders (24%) suggests
that more awareness is needed to raise the role and function of
DTCs in both ambulatory and hospital care, and its link in
promoting RUM, given concerns with their implementation and
effectiveness especially in LMICs (Lima-Dellamora Eda et al.,
2014; Matlala et al., 2017; Fadare et al., 2018; Mashaba et al.,
2019). According to the WHO, the goal of DTCs is to ensure
access to the best possible cost effective and high quality of care
through determining what medicines will be available at what
cost and how will they be used (World Health Organization,
2003; Lima-Dellamora Eda et al., 2014). The important work of
DTCs includes establishing documented rules and policies for all
aspects of drug management including the selection of formulary
list medicines and agreement regarding treatment protocols
should be emphasized and reassessed for learnings. Other
functions include continuing education for all key stakeholder
groups, auditing and feedback, drug utilization reviews, and
monitoring of adverse reactions and medication errors to
promote RUM (Godman et al., 2009; Lima-Dellamora Eda
et al., 2014; Meyer et al., 2017; Mashaba et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 11Nevertheless, it still remains unclear how DTCs with this
important mandate represented by these activities failed to
have a critical role in promoting RUM compared to clinical
guidelines. More research is needed to uncover the reasons
behind this to provide future direction given the critical role
that DTCs including formularies have played with enhancing the
RUM (Holloway and Green, 2003; Godman et al., 2009;
Thawani, 2010; Holloway et al., 2018; Sabir, 2018), and we will
be exploring this further in the future.
Furthermore, there is a clear need for clarity over the linkage
between HTA and RUM. It is noted that RUM is a strategy that is
applied through various structures across different tiers and levels.
This assumes HTA as one corner stone structure that safe-guards
RUM policies. Nevertheless, the healthcare community is yet to
deﬁne the nature and depth of the relationship between the two.
This may be because HTA can be linked more to reimbursement
and funding decisions for new medicines across countries rather
than a key role in guideline development. Similar to HTA practice,
RUM policies aim to optimize treatment processes and cut waste.
An example of a long-lasting research program, funded by the
Ministry ofHealth, andwhereHTA andRUMcome together is the
Rational Use of Pharmacotherapy of ZonMw in the Netherlands
(ZonMw, 2015; ZonMw, 2019).
Regarding the survey results, it is imperative to reﬂect on how
RUM interventions are carried forward by different entities and
bodies within the healthcare system, and how these entities
translate RUM strategies into action. Equally important is the
role of HTA as a function and practice, and how HTA entitiesFIGURE 8 | Challenges to support local entities in enhancing RUM (n = 62).March 2020 | Volume 11 | Article 144
Gad et al. CORUM in Europeestablish a harmonized relationship with the remaining
structures/entities that promote RUM implementation. This
consequently entails more research on establishing an effective
governance system across all involved entities and stakeholders
to effectively incentivize and deliver RUM interventions to
improve patient care.
Finally, it is important to emphasize that educational activities
remain the most important interventions to improve RUM.
Compared to engineering, economics, and enforcement,
education related initiatives were perceived as the most important
to address challengeshinderingoptimalRUM.This includes raising
awareness on RUM to a wider group of stakeholders including
governmentofﬁcials, patients, practitioners, and thepublic.Theaim
wouldbe to focus onhowbest to achievebetterutilizationof current
interventions to enhance RUM, and how can these interventions be
assessed, evaluated, andmodiﬁed to appeal to different stakeholders
as well as raise the level of understanding of the concept of RUM.
These are projects for the future especially among Central and
Eastern European countries.
We were aware of a number of limitations with this study.
Firstly, the respondents taking part in the study were not
representative of all key stakeholder groups. However, those
taking part were actively involved in initiatives in their own
countries to try and enhance RUM through different
mechanisms. Secondly, some respondent groups had a high
proportion of Piperska members. Thirdly, we did not fully
query all the interventions such as “avoidance of perverse
ﬁnancial incentives” as we believed it’s a very complex issue
that is difﬁcult to capture through one question. Lastly, the low
response rate. However, we expect the impact of a higher
response rate would have been limited and would not have
appreciably altered the conclusions drawn as our target sample
was highly speciﬁc. Consequently, those who responded are
believed to be well representative of the healthcare community
involved with RUM in their country to give good guidance. As a
result despite these limitations, we believe the ﬁndings provide
relevant insights into current RUM initiatives and challenges
within Europe with the research team seeking to maximize the
survey tool to obtain results that are as accurate as possible.CONCLUSION
In conclusion, the importance of the RUM cannot be overstated
given the growing pressure on healthcare resources across
countries. Whilst our ﬁndings point to the importance of the
key interventions surveyed, especially around clinical guidelineFrontiers in Pharmacology | www.frontiersin.org 12development, the results suggest that the stakeholders are keen to
develop better utilization of these interventions, investing in their
appropriate application in practice. This can be achieved most
prominently by increasing educational initiatives around RUM,
and to call on creating mechanisms linking rational use of
medicines with the HTA function already developed in most
European countries. There is also a clear role for groups such as
WHO Europe, especially in Central and Eastern European
countries, EUNetHTA, Piperska, HTAi, EuroDURG, and
patient groups such as EUPATI to enhance RUM through
their various activities and initiatives. In particular, this
includes encouraging countries and stakeholders to learn from
each other and to collaborate in order to improve RUM building
on existing Pan-European networks. We will be following this up
in the future including re-evaluating progress in this area.DATA AVAILABILITY STATEMENT
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